A
4.41
0.13 (3.04%)
| Previous Close | 4.28 |
| Open | 4.45 |
| Volume | 80,882 |
| Avg. Volume (3M) | 788,574 |
| Market Cap | 118,938,576 |
| Price / Book | 0.590 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -2.38 |
| Total Debt/Equity (MRQ) | 8.95% |
| Current Ratio (MRQ) | 13.10 |
| Operating Cash Flow (TTM) | -45.93 M |
| Levered Free Cash Flow (TTM) | -35.43 M |
| Return on Assets (TTM) | -32.36% |
| Return on Equity (TTM) | -56.72% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Alto Neuroscience, Inc. | Bearish | - |
AIStockmoo Score
-0.8
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.75 |
|
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 7.51% |
| % Held by Institutions | 91.30% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Alpha Wave Global, Lp | 30 Sep 2024 | 3,707,757 |
| Ra Capital Management, L.P. | 30 Sep 2024 | 2,075,154 |
| 72 Investment Holdings, Llc | 30 Sep 2024 | 667,778 |
| Vestal Point Capital, Lp | 30 Sep 2024 | 650,000 |
| Awm Investment Company, Inc. | 30 Sep 2024 | 559,731 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 18.00 (Jones Trading, 308.16%) | Buy |
| Median | 10.00 (126.76%) | |
| Low | 4.00 (Wedbush, -9.30%) | Hold |
| Average | 10.50 (138.10%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 4.25 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jones Trading | 16 Dec 2024 | 18.00 (308.16%) | Buy | 3.75 |
| Stifel | 13 Nov 2024 | 10.00 (126.76%) | Buy | 4.53 |
| Baird | 23 Oct 2024 | 10.00 (126.76%) | Buy | 4.36 |
| Wedbush | 23 Oct 2024 | 4.00 (-9.30%) | Hold | 4.36 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Dec 2024 | Announcement | Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology |
| 12 Nov 2024 | Announcement | Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights |
| 04 Nov 2024 | Announcement | Alto Neuroscience to Participate in Upcoming Investor Conferences |
| 22 Oct 2024 | Announcement | Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |